Kyverna Therapeutics, Inc. Common Stock
Symbol: KYTX (NASDAQ)
7.06
▼ (-1.18%) -0.084
Company Description:
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Key Stats
- Today's Open: $7.14
- Today's High: $7.14
- Today's Low: $7.056
- Today's Volume: 4
- Yesterday Close: $7.14
- Yesterday High: $7.57
- Yesterday Low: $7.03
- Yesterday Volume: 382.64K
- Last Min Volume: 0
- Last Min High: $7.126
- Last Min Low: $7.056
- Last Min VWAP: $0
Company Profile
- Name: Kyverna Therapeutics, Inc. Common Stock
- Website: https://www.kyvernatx.com
- Listed Date: 2024-02-08
- Location: EMERYVILLE, CA
- Market Status: Active
- CIK Number: 0001994702
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $324.34M
- Round Lot: 100
- Outstanding Shares: 43.25M
- Asset Type: CS
RECENT FILINGS FOR KYTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-25 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-01 | 4 | View |
| 2025-07-01 | 3 | View |
| 2025-06-30 | 8-K | View |
| 2025-06-03 | 8-K | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 8-K | View |
| 2025-04-15 | EFFECT | View |
| 2025-04-15 | 4 | View |
| 2025-04-15 | 4 | View |
| 2025-04-15 | 4 | View |
| 2025-04-15 | 424B5 | View |
Latest News on KYTX